Market research
IDXG Interpace Biosciences, Inc
OTCQX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 42M
- P/E ratio
- 1.69
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.61
Profile
Company facts
- Exchange
- OTCQX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US46062X3035
- Market cap
- 42M
- P/E ratio
- 1.69
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 0.61
About
About Interpace Biosciences, Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IDXG discussion.
5 years, 4 months ago
Interpace Biosciences, Inc is currently in a long term uptrend where the price is trading 72.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Interpace Biosciences, Inc's total revenue rose by 128.8% to $10M since the same quarter in the previous year.
Its net income has increased by 24.2% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 70.7% to $-2M since the same quarter in the previous year.
Based on the above factors, Interpace Biosciences, Inc gets an overall score of 5/5.